Vor Biopharma Inc (VOR) - News Archive

Transformative Advances in IgA Nephropathy: Vor Bio s Promising Phase 3 Clinical Data Presentation at ASN Kidney Week 2025 In a groundbreaking development that is set to captivate the nephrology community, Vor Bio, a pr...

In the rapidly evolving landscape of cancer therapy, Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company headquartered in Cambridge, Massachusetts, has emerged as a frontrunner in the development...

Cambridge-based Vor Bio Announces Material Inducement Grants to Newly Hired Employees Under Nasdaq Listing Rule 5635(c)(4)In a recent press release, clinical-stage cell and genome engineering company Vor Bio (Nasdaq: VO...

Vor Bio Grants Inducement Stock Options and RSUs to New EmployeesVor Bio, a clinical-stage cell and genome engineering company, recently announced that the Compensation Committee of the Board of Directors granted stock...

Vor Bio, a clinical-stage cell and genome engineering company based in Cambridge, Massachusetts, has announced a series of inducement grants to newly hired employees. The company s Compensation Committee of the Board of...

CAMBRIDGE, Mass., May 3, 2024 - Vor Bio (Nasdaq: VOR), a leading clinical-stage cell and genome engineering company, announced today the granting of stock options and restricted stock units (RSUs) to six newly hired emp...

Vor Bio s Inducement Grants Drive Talent Acquisition and Reflect Positive Growth CAMBRIDGE, Mass., March 05, 2024 - Vor Bio (Nasdaq: VOR), a leading clinical-stage cell and genome engineering company, has recently discl...

Clinical-stage cell and genome engineering firm Vor Bio proudly announced on January 17, 2024, that it has accomplished a crucial first step towards developing a new therapy for acute myeloid leukemia (AML) by dosing th...

Vor Bio, a clinical-stage cell and genome engineering company, has recently made a significant announcement regarding the grant of stock options and restricted stock units (RSUs) to four newly hired employees. This move...

IntroductionIn a recent press release, Vor Bio, a clinical-stage cell and genome engineering company, announced the granting of stock options and restricted stock units (RSUs) to five newly hired employees. This move is...